Solis-Hernandez, Mª PilarFernandez Del Valle, AnaCarmona-Bayonas, AlbertoGarcia-Carbonero, RocioCustodio, AnaBenavent, MartaAlonso Gordoa, TeresaNuñez-Valdovino, BárbaraSanchez Canovas, ManuelMatos, IgnacioAlonso, VicenteLopez, CarlosViudez, AntonioIzquierdo, MartaCalvo-Temprano, DavidGrande, EnriqueCapdevila, JaumeJimenez-Fonseca, Paula2023-01-252023-01-252019-09-03http://hdl.handle.net/10668/14466The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression. One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7-15.9) and 15.8 months (95% CI, 13.9-25.7). PFS by Choi (Kendall's τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival. Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AdultAgedAged, 80 and overAntineoplastic AgentsConfidence IntervalsFemaleHumansMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsProgression-Free SurvivalProportional Hazards ModelsProspective StudiesResponse Evaluation Criteria in Solid TumorsSunitinibTomography, X-Ray ComputedTumor BurdenYoung Adultresearch article31477779open access10.1038/s41416-019-0558-71532-1827PMC6889276https://www.nature.com/articles/s41416-019-0558-7.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889276/pdf